NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Avastin and Taxotere for Esophagogastric Cancer

CompletedPhase 2

Sponsor: Dana-Farber Cancer Institute

Conditions: Esophageal Cancer, Gastric Cancer

Interventions: Docetaxel, Bevacizumab

Countries: United States

The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric carcinoma
* Measurable disease greater than or equal to 1cm by spiral computed tomography (CT) scan or greater than or equal to 2cm by other radiographic technique
* ECOG performance status 0-2
* One prior chemotherapy for metastatic disease permitted
* White blood cell count greater than or equal to 3,000/mm
* Absolute neutrophil count greater than or equal to 1,500/mm3
* Platelet count greater than or equal to 100,000/mm3
* Hemoglobin greater than or equal to 8.0g/dl
* Creatinine less than 2.0mg/dL
* Total bilirubin less than 1.9mg/dL

Exclusion Criteria:

* Pregnant or lactating women
* History or evidence of central nervous system (CNS) disease
* Other active malignancies other than non-melanoma skin cancer or in-situ cervical cancer
* History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with polysorbate 80.
* Current, recent or planned treatment with standard chemotherapy, radiation therapy or another experimental therapy.
* History of other disease or metabolic dysfunction.
* Serious, non-healing wound, ulcer, or bone fracture.

Locations (3)

Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States